AstraZeneca axes another R&D track on durvalumab after once again falling behind rivals
It’s not easy being fourth.
The R&D team at AstraZeneca had thought that its single-arm study for its Phase II trial of the PD-L1 checkpoint …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
